PE20120125A1 - Combinacion antitumoral que asocia ave8062 y docetaxel - Google Patents

Combinacion antitumoral que asocia ave8062 y docetaxel

Info

Publication number
PE20120125A1
PE20120125A1 PE2011001197A PE2011001197A PE20120125A1 PE 20120125 A1 PE20120125 A1 PE 20120125A1 PE 2011001197 A PE2011001197 A PE 2011001197A PE 2011001197 A PE2011001197 A PE 2011001197A PE 20120125 A1 PE20120125 A1 PE 20120125A1
Authority
PE
Peru
Prior art keywords
ave8062
docetaxel
administered
tumor combination
combination associating
Prior art date
Application number
PE2011001197A
Other languages
English (en)
Inventor
Michele Besenval
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20120125A1 publication Critical patent/PE20120125A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION ANTITUMORAL QUE COMPRENDE: A) EL COMPUESTO (Z)-N-[2-METOXI-5-[2-(3,4,5-TRIMETOXIFENIL)VINIL]FENIL]-L-SERINAMIDA (AVE8062) QUE SE ADMINISTRA EN UNA DOSIS DE 10 A 50MG/M2; Y B) DOCETAXEL QUE SE ADMINISTRA EN UNA DOSIS DE 50 A 120MG/M2; EN DONDE EL DOCETAXEL SE ADMINISTRA DESPUES DE UN INTERVALO DE 24 HORAS DE ADMINISTRADO EL AVE8062 Y ADEMAS EL INTERVALO ENTRE DOS ADMINISTRACIONES DE AVE8062 ES DE 3 SEMANAS. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER DE OVARIO, DE PANCREAS, DE VEJIGA, DE HIGADO
PE2011001197A 2008-12-12 2009-12-10 Combinacion antitumoral que asocia ave8062 y docetaxel PE20120125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806979A FR2939665B1 (fr) 2008-12-12 2008-12-12 Combinaison antitumorale associant l'ave8062a et le docetaxel

Publications (1)

Publication Number Publication Date
PE20120125A1 true PE20120125A1 (es) 2012-02-23

Family

ID=40790630

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001197A PE20120125A1 (es) 2008-12-12 2009-12-10 Combinacion antitumoral que asocia ave8062 y docetaxel

Country Status (27)

Country Link
US (1) US20120004294A1 (es)
EP (1) EP2376076A1 (es)
JP (1) JP2012511554A (es)
KR (1) KR20110104932A (es)
CN (1) CN102245175A (es)
AR (1) AR074599A1 (es)
AU (1) AU2009326220A1 (es)
BR (1) BRPI0923349A2 (es)
CA (1) CA2746475A1 (es)
CL (1) CL2011001316A1 (es)
CO (1) CO6390037A2 (es)
CR (1) CR20110319A (es)
EA (1) EA201170803A1 (es)
EC (1) ECSP11011112A (es)
FR (1) FR2939665B1 (es)
IL (1) IL213458A0 (es)
MA (1) MA32955B1 (es)
MX (1) MX2011006253A (es)
NI (1) NI201100114A (es)
PA (1) PA8853301A1 (es)
PE (1) PE20120125A1 (es)
SG (1) SG172071A1 (es)
TN (1) TN2011000268A1 (es)
TW (1) TW201032798A (es)
UY (1) UY32318A (es)
WO (1) WO2010067027A1 (es)
ZA (1) ZA201104358B (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
EP1351573A4 (en) 2000-12-22 2007-03-28 Bristol Myers Squibb Co METHOD FOR MODULATING TUMOR WATCHTOWER AND METASTASIS
US20050209310A1 (en) 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines

Also Published As

Publication number Publication date
CN102245175A (zh) 2011-11-16
JP2012511554A (ja) 2012-05-24
ZA201104358B (en) 2012-09-26
EA201170803A1 (ru) 2011-12-30
MX2011006253A (es) 2011-11-04
AR074599A1 (es) 2011-01-26
EP2376076A1 (fr) 2011-10-19
AU2009326220A1 (en) 2011-07-07
CA2746475A1 (fr) 2010-06-17
WO2010067027A1 (fr) 2010-06-17
CR20110319A (es) 2011-09-20
ECSP11011112A (es) 2011-07-29
KR20110104932A (ko) 2011-09-23
FR2939665A1 (fr) 2010-06-18
TW201032798A (en) 2010-09-16
FR2939665B1 (fr) 2011-10-07
US20120004294A1 (en) 2012-01-05
UY32318A (es) 2010-07-30
NI201100114A (es) 2011-12-13
TN2011000268A1 (fr) 2012-12-17
IL213458A0 (en) 2011-07-31
PA8853301A1 (es) 2010-07-27
BRPI0923349A2 (pt) 2015-07-21
MA32955B1 (fr) 2012-01-02
CL2011001316A1 (es) 2011-10-28
CO6390037A2 (es) 2012-02-29
SG172071A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
UY37998A (es) Agentes antivirales contra la hepatitis b
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CR20120625A (es) Métodos de tratamiento contra el cáncer pancreático
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
EA201490254A1 (ru) Комбинированное лечение гепатита с
PE20140604A1 (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
TW200744568A (en) Epinephrine dosing regimens
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
MX2009005798A (es) Recuperacion de apoplejia.
EA201690327A1 (ru) Терапевтические способы
PE20100264A1 (es) Metodos para utilizar composiciones de liberacion sostenida de aminopiridina
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
PE20120125A1 (es) Combinacion antitumoral que asocia ave8062 y docetaxel
NO20092230L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.

Legal Events

Date Code Title Description
FC Refusal